NCT02891161 - Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

August 6, 2019

Study Completion Date

April 27, 2022

Conditions

Urothelial Cancer

Interventions

DRUG

durvalumab

1500 mg Q4 weekly

RADIATION

Radiation Therapy

64.8 Gy, 36 daily fractions on weekdays over about 7 weeks

Trial Locations (7)

Montefiore Medical Center, The Bronx

Penn State Cancer Intsitute, Hershey

University of Iowa Hospital and Clinics, Iowa City

Froedtert & The Medical College of Wisconsin, Milwaukee

University of Wisconsin, Madison

Nebraska Methodist Hospital, Omaha

Rutgers Cancer Institute of New Jersey, New Brunswick